Comparative effects of pirenzepine and cimetidine, alone and in combination, on 24-hour gastric acidity in duodenal ulcer disease
- PMID: 6394132
Comparative effects of pirenzepine and cimetidine, alone and in combination, on 24-hour gastric acidity in duodenal ulcer disease
Abstract
Both pirenzepine and cimetidine have been shown to be beneficial in the healing of duodenal ulcers. The aim of the present study was to determine the effects of 50 mg of pirenzepine BID and 600 mg of cimetidine BID, either alone or in combination, on 24-hour intragastric acidity, nocturnal gastric secretory volume and acid output, and serum gastrin profile in patients with duodenal ulcers. Eight asymptomatic patients with healed duodenal ulcers received placebo, pirenzepine, cimetidine, or cimetidine plus pirenzepine for one week each in a sequential order. All measurements were performed over a 24-hour period on the last day of each treatment week. Compared with pirenzepine, cimetidine was associated with lower hydrogen ion (H+) activities after breakfast, during the night, and over the 24-hour period. Pirenzepine alone failed to suppress H+, but the combination of cimetidine plus pirenzepine resulted in more prolonged acid suppression, with lower H+ after lunch, than did cimetidine alone. The effect of cimetidine on the suppression of nocturnal acid secretory volume and acid output was further enhanced by the addition of pirenzepine. The fasting serum gastrin concentrations were similar in all treatments, excluding one patient with antral G-cell hyperplasia; the postprandial gastrin responses were similarly higher with cimetidine and cimetidine plus pirenzepine than with pirenzepine. The findings suggest an added benefit of combination therapy with cimetidine and pirenzepine that may be useful in patients who fail to respond to single-agent therapy.
Similar articles
-
Comparative effects of two cimetidine regimens on 24-hour intragastric acidity in patients with asymptomatic duodenal ulcer.Clin Ther. 1984;6(3):259-81. Clin Ther. 1984. PMID: 6373006 Clinical Trial.
-
Interrelationship between gastric acidity and gastrin concentration in patients with duodenal or gastric ulcer and in healthy subjects.Clin Ther. 1985;7(4):424-41. Clin Ther. 1985. PMID: 4016826
-
Comparison between ranitidine, cimetidine, pirenzepine and placebo in the short term treatment of duodenal ulcer.Scand J Gastroenterol Suppl. 1982;72:215-9. Scand J Gastroenterol Suppl. 1982. PMID: 6291138 Clinical Trial.
-
Cholecystokinin in the control of gastric acid and plasma gastrin and somatostatin secretion in healthy subjects and duodenal ulcer patients before and after eradication of Helicobacter pylori.J Physiol Pharmacol. 1994 Dec;45(4 Suppl 1):3-66. J Physiol Pharmacol. 1994. PMID: 7787215 Review.
-
[Effect of 300 mg of ranitidine, 800 mg of cimetidine and a placebo administered after the evening meal on 24-hour gastric pH in patients with duodenal ulcer].Gastroenterol Clin Biol. 1988 Dec;12(12):941-5. Gastroenterol Clin Biol. 1988. PMID: 3069551 Review. French.
Cited by
-
Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs.Gut. 1987 Sep;28(9):1120-7. doi: 10.1136/gut.28.9.1120. Gut. 1987. PMID: 2890561 Free PMC article. Clinical Trial.
-
Comparison of the effects of gastric antisecretory agents in healthy volunteers and patients with duodenal ulcer.Gut. 1986 Sep;27(9):1058-61. doi: 10.1136/gut.27.9.1058. Gut. 1986. PMID: 3758819 Free PMC article.
-
Pharmacokinetic and pharmacodynamic studies in man simulating acute and chronic treatment with oral pirenzepine.Eur J Clin Pharmacol. 1989;36(4):369-74. doi: 10.1007/BF00558297. Eur J Clin Pharmacol. 1989. PMID: 2737229
-
Interaction of magnesium oxide with gastric acid secretion inhibitors in clinical pharmacotherapy.Eur J Clin Pharmacol. 2014 Aug;70(8):921-4. doi: 10.1007/s00228-014-1694-x. Epub 2014 May 13. Eur J Clin Pharmacol. 2014. PMID: 24820768 Clinical Trial.